ArticleDermatology practical & conceptual2024
mTORC1 and mTORC2 Levels in Patients with Psoriasis.
Article in Dermatology practical & conceptual, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of mitophagy-related biomarkers with immune cell infiltration in psoriasis.BMC medical genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn recent years, there has been a growing emphasis on the role of the mammalian target of rapamycin (mTOR) pathway in the pathogenesis of psoriasis. This intracellular signaling pathway is known as the main control pathway of metabolism and is of particular interest in this context.
objectivesTo investigate the importance of the mTOR pathway in the pathogenesis of plaque psoriasis.
methodsA total of forty patients with plaque psoriasis and 40 non-psoriatic volunteers were included in this case-control study. The fasting serum levels of mTORC1 and mTORC2 in the study groups were examined by enzyme-linked immunosorbent assay.
resultsSerum levels of both mTORC1 and mTORC2 were found to be significantly lower in patients with plaque psoriasis than in controls (P = 0.001). A positive correlation was identified between serum mTORC1 and serum mTORC2 levels in patients with plaque psoriasis (p=0.001, r=0.826).
conclusionThe lower serum levels of mTORC1 and mTORC2 complexes, which are active signaling molecules in the cell, were observed in patients with plaque psoriasis. This suggests that these levels may serve as an indicator of increased intracellular activation of these molecules. It is our opinion that agents that can effectively inhibit both mTOR complexes may be more effective in the treatment of psoriasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.